Abstract

Dr. Bharath KumarV.D.*, Dr. Jayanthi C. R. and Dr. Sushma M.

ABSTRACT

Background: Helicobacter pylori infection is a widespread disease leading to significant morbidity and mortality, requiring an appropriate therapeutic approach. Non-compliance to H. pylori eradication is mainly associated with side effects like diarrhea. Probiotics improve the antibiotic tolerability by reducing side effects which in-turn leads to improvement in quality of life of patients. Objective: To assess tolerability among patients with or without synbiotic supplementation in H. pylori eradication regimen. Methods: A prospective comparative study was conducted in 100 Peptic Ulcer Disease (PUD) patients diagnosed with H. pylori and the patients were randomly assigned into two treatment groups of 50 patients each. One group received Lansoprazole, Amoxicillin and Clarithromycin (LAC group) and other group received a synbiotic, Lansoprazole, Amoxicillin and Clarithromycin (SLAC group). Incidence of Adverse Drug Reaction(ADR) and tolerability was assessed using a standardized questionnaire given to the patient at the time of enrollment. Results: The total incidence of ADR was less in SLAC group compared to LAC group (30% vs 46%).SLAC group patients experienced less incidence of ADR in terms of of diarrhea( 10% vs 30%), nausea (10% vs 36.66%) and taste disturbances(16.66% vs 40%) relative to LAC group patients. Tolerability was better in SLAC Group compared to LAC Group at day 14 but not statistically significant.